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Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine tumor with high mortality rates. Merkel
cell polyomavirus (MCPyV), identified in the majority of MCCs, may drive tumorigenesis via viral T antigens.
However, the mechanisms underlying pathogenesis in MCPyV-negative MCCs remain poorly understood.
To nominate genes contributing to the pathogenesis of MCPyV-negative MCCs, we performed DNA microarray
analysis on 30 MCCs. The MCPyV status of MCCs was determined by PCR for viral DNA and RNA. A total of 1,593
probe sets were differentially expressed between MCPyV-negative and MCPyV-positive MCCs, with significant
differential expression defined as at least a 2-fold change in either direction and a P-valuep0.05. MCPyV-negative
tumors showed decreased RB1 expression, whereas MCPyV-positive tumors were enriched for immune response
genes. Validation studies included immunohistochemistry demonstration of decreased RB protein expression in
MCPyV-negative tumors and increased peritumoral CD8þ T lymphocytes surrounding MCPyV-positive tumors.
In conclusion, our data suggest that loss of RB1 expression may have an important role in the tumorigenesis of
MCPyV-negative MCCs. Functional and clinical validation studies are needed to determine whether this tumor-
suppressor pathway represents an avenue for targeted therapy.
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INTRODUCTION
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine
tumor of the skin with high rates of recurrence, metastasis,
and mortality. The incidence of MCC has nearly tripled in the
past 20 years, and this malignancy is more prevalent in the
immunosuppressed and the elderly. The 5-year overall survi-
val from the time of diagnosis is 30–64%. Survival decreases
upon metastasis to lymph nodes, distant skin sites, or distant
organs (Bichakjian et al., 2007).
There is an increased risk for MCC in solid organ transplant
recipients, chronic lymphocytic leukemia patients, and HIV-
infected patients, suggesting an infectious etiology for this
malignancy (Kuhajda et al., 1986; Penn and First, 1999; Engels
et al., 2002; Bhatia et al., 2011). The DNA of Merkel cell
polyomavirus (MCPyV), has been identified in B80% of
MCCs (Feng et al., 2008; Foulongne et al., 2008; Kassem
et al., 2008; Becker et al., 2009; Garneski et al., 2009; Katano
et al., 2009; Bhatia et al., 2011; Brewer et al., 2012). MCPyV
may contribute to tumorigenesis via a truncated large
T antigen (LTAg) and small T antigen (STAg), which
inhibit the tumor-suppressor RB and promote signaling by
the mammalian target of rapamycin pathway, respectively
(Shuda et al., 2008, 2011; Houben et al., 2012). The
mechanisms of tumorigenesis specific to MCPyV-negative
tumors are less well understood, although altered expression
of RB, p53, and/or c-KIT suggest that these molecules may
have a role (Bhatia et al., 2010b; Sihto et al., 2011; Waltari
et al., 2011).
To our knowledge, transcriptional profiles of MCPyV-nega-
tive and MCPyV-positive tumors have not been compared. To
nominate candidate genes involved in MCPyV-independent
MCC tumorigenesis, we performed DNA microarray analysis
of MCC tumors and correlated profiling results with MCPyV
tumor status.
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RESULTS
Patient demographics
Patient demographic information is summarized in Table 1.
The study included 30 tumors from 27 patients (14 men and
13 women) diagnosed with MCC between 2005 and 2010.
The mean patient age at diagnosis was 75 years. Two patients
were immunosuppressed at the time of diagnosis because
of organ transplant. Two additional patients had chronic
lymphocytic leukemia.
Transcriptional profiling demonstrates distinct gene expression
patterns in MCC compared with other primary cutaneous
carcinomas
To characterize gene expression patterns in MCC, we analyzed
transcriptional profiles of 19 primary MCCs, 11 metastatic
MCCs, 3 MCC cell lines, 4 primary cutaneous squamous cell
carcinomas (SCCs), and two basal cell carcinomas (BCCs).
Oligonucleotide arrays with over 54,000 probe sets representing
over 47,400 transcripts were used. To generate an unsupervised
two-dimensional representation of relative gene expression
across all tumors, we performed principal component analysis
of all probe sets. The resulting principal component analysis plot
demonstrated clear distinction of MCCs from SCCs and BCCs,
with only one outlier (Figure 1). Cultured MCC cells, which
represent a pure population of tumor cells, assorted with MCC
tumor specimens. The single MCC outlier case was morpholo-
gically similar to other MCC tumors in the cohort, but had lower
tumor volume than other samples.
For all analyses, significant differential expression was
defined as at least a 2-fold differential expression in either
direction, with an adjusted P-value of p0.05. Relative to
SCCs, MCCs demonstrated significant differential expression
of over 4,000 probe sets (Supplementary Figure S1 and
Supplementary Table S1 online, and data not shown), with a
false discovery rate of 1.8%. In validation of our approach,
our screen identified established diagnostic markers of MCCs
including cytokeratin 20, chromogranin A, synaptophysin, and
neural cell adhesion molecule 1, as well as known markers
for SCCs such as cytokeratin 5/6 and tumor protein 63
(Supplementary Table S1 online). In addition, we observed
upregulation of the proposed mechanoreceptor genes Piezo2
(FAM38B) and TRPC1 (Chalfie, 2009; Coste et al., 2010;
Garrison et al., 2011). To screen for upregulated genes with
potential roles in tumorigenesis, we searched the data set for
the term ‘‘oncogene’’ in the gene description, and filtered
these candidates by literature search to identify genes with
known roles in cancer biology. Using this method, we
identified potentially protumorigenic genes including FYN,
AKT3, MYB, RAB3B, JUND, and FEV (Supplementary Table
S1 online) (Peter et al., 1997; Ramsay and Gonda, 2008; Saito
et al., 2010; Hers et al., 2011; Nakayama et al., 2012; Tan
et al., 2012). In further validation of our data set, we also
found upregulation of genes previously reported to be
expressed in MCC, including SOX2, BCL2, MYCL1, VEGFA,
GPC3, ATOH1, HIP1, and KIT (Supplementary Table S1
online) (Kennedy et al., 1996; Moll et al., 1996; Plettenberg
et al., 1996; Ben-Arie et al., 2000; Leonard et al., 2002; Su
et al., 2002; Fernandez-Figueras et al., 2007; Brunner et al.,
2008; He et al., 2009; Paulson et al., 2009; Laga et al., 2010;
Ames et al., 2011). We also identified upregulation of
numerous genes previously described as expressed in benign
Merkel cells, including neuronal transcription factors,
presynaptic molecules, and ion channels (Supplementary
Table S1 online) (Haeberle et al., 2004).
The group of overexpressed or underexpressed genes in
MCCs relative to SCCs was assessed for functional clusters by
Gene Ontology (GO) analysis, which revealed that MCCs
were enriched for gene sets associated with neural differentia-
tion (Supplementary Table S2 online). Comparison with a
database of gene expression profiles via parametric gene set
analysis revealed similarity between MCCs and tumors
including neuroblastoma (Supplementary Figure S2 online).
A comparison of MCCs with BCCs yielded 650 significantly
different probe sets. Genes upregulated in BCCs relative to
MCCs included the Hedgehog pathway transcripts GLI1,
GLI2, PTCH1, and PTCH2, as well as the Hedgehog target
basonuclin (Supplementary Table S3 online), consistent with
the known role of Hedgehog signaling in BCCs (Cui et al.,
2004; Kasper et al., 2012).
In silico comparison of MCCs with normal skin demonstrated
a significant difference in expression in 48,000 probe sets,
with significant differential expression defined as at least 2-fold
differential expression in either direction, with an adjusted
P-value of p0.05. The principal component analysis demon-
strated clear separation between groups (Supplementary Figure
S3 online). We observed differential expression of MCC
diagnostic markers, proposed mechanoreceptor genes, and
protumorigenic genes (Supplementary Table S4 online).
MCPyV status and clinical features
By PCR detection of MCPyV DNA and RNA, we found that
12/26 (46%) tumors in our cohort were MCPyV-positive and
14/26 (54%) were MCPyV-negative (Supplementary Figure S4
online). There was no significant difference in age at diagnosis
and stage at presentation between MCPyV-negative and
MCPyV-positive groups. Tumors showed significantly different
anatomic distribution by MCPyV status (P¼0.029). Specifi-
cally, 8 of 11 (73%) MCPyV-negative primary tumors were
located in the head and neck region and 3 (27%) were on the
upper extremities, whereas none was on the lower extremity.
In contrast, 3 of 12 (25%) MCPyV-positive primary tumors
were located on the head and neck, 4 (33%) on the upper
extremity, and 5 (42%) on the lower extremity.
Transcriptional profiling identifies distinct gene expression
patterns in MCPyV-negative MCCs
We analyzed gene expression patterns in MCPyV-positive
versus MCPyV-negative tumors. By principal component
analysis of all probe sets, the majority of MCPyV-positive
tumors formed a cluster, which displayed partial overlap with
MCPyV-negative tumors (Figure 2). A total of 1,593 probe sets
displayed significant differential expression between MCPyV-
positive and -negative tumors, with a false discovery rate of
1.9% (Figure 3 and data not shown). By GO and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway
analyses, MCPyV-negative tumors displayed relative
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upregulation of gene groups associated with Notch signaling
and receptor tyrosine kinase signaling, among others (Table 2
and data not shown).
MCPyV-positive tumors are enriched for peritumoral
lymphoctyes
The GO and KEGG analyses identified enrichment for a
number of gene groups associated with immune response in
the MCPyV-positive tumor cohort including CD3G, CD3D,
ZAP70, and IGHM, suggesting increased presence of tumoral
lymphocytes. Thus, we performed immunohistochemical
studies to define the immune infiltrate associated with
MCPyV-positive tumors. Relative to MCPyV-negative tumors,
MCPyV-positive tumors were associated with significantly
increased CD8þ cells (fold 14.0, P¼ 0.01; Figure 4). There
was also a trend toward increased CD3þ cells (fold 3.1,
Table 1. Patient and tumor characteristics of profiled cases
Primary tumor
Patient
no.
Case
no.
Tumor type/
source Gender
Stage at
diagnosis
Age at
diagnosis
Immuno-
suppression Outcome
Time to outcome
(months)
Breslow
(mm) Body site MCPyV1
1 1 Primary/skin M 3 65 No DOD 13 X7 Shoulder Negative
2 2 Primary/skin F 1 82 No DOC 36 ND Leg Positive
3 3 Primary/skin M 2 88 No DOC 23 46 Leg Positive
4 4 Primary/skin M 1 81 No AWED 41 3.3 Forehead Negative
5 5 Primary/skin M 1 59 Yes DOD 15 42.2 Ear Negative
6 6 Primary/skin M 1 70 No AWED 33 44 Ear Negative
7 7 Primary/skin F 1 85 No LTFU 5.5 Cheek Positive
8 8 Primary/skin F 2 68 No AWED 37 1.85 Leg ND
9 9 Primary/skin F 2 77 No AWED 7 X9 Eyelid Positive
10 10 Primary/skin M 3 80 No AWED 18 X4.1 Arm Positive
11 11 Primary/skin M 1 59 No AWED 13 3.8 Arm Positive
12 12 Primary/skin F 1 75 No AWED 12 4.8 Leg Positive
13 13 Primary/skin M 1 85 No AWED 6 9 Hand Negative
14 14 Primary/skin F 2 77 No AWED 12 X9 Cheek Negative
15 15 Primary/skin M 2 78 No DOD 7 3.1 Cheek Negative
16 16 Primary/skin M 1 80 No AWED 6 X2.5 Leg Positive
17 17 Metastasis/skin F 3 78 No DOD 14 6 Leg ND
18 18 Metastasis/skin M 3 85 No DOD 12 X5 Nose Negative
19 19 Metastasis/skin M 3 69 No DOD 17 46 Temple Negative
20 20 Metastasis/skin F 3 67 Yes2 DOD 16 10 Forearm Positive
21 21 Metastasis/skin F 3 57 No AWED 62 ND Foot Positive
22 22 Metastasis/
parotid
F 3 85 No DOD 9 18 Cheek Positive
23 23 Metastasis/
parotid
F 3 90 No AWED 12 9 Temple Negative
24 24 Metastasis/LN F 3 79 No AWED 20 12 Arm Positive
25 25 Primary/skin F 2 85 No DOD 27 ND Arm ND
(25) 26 Metastasis/skin Negative
26 27 Primary/skin M 2 53 Yes AWRD 10 19 Arm Negative
(26) 28 Metastasis/LN Negative
27 29 Primary/skin M 1 71 Yes2 DOD 25 4 Neck Equivocal
(27) 30 Metastasis/
parotid
Negative
Abbreviations: AWED, alive without evidence of disease; AWRD, alive with residual disease; DOC, died of other causes; DOD, died of disease; F, female;
LN, lymph node; LTFU, lost to follow-up; M, male; MCPyV, Merkel cell polyomavirus; ND, not determined (because of lack of PCR-quality DNA in the case
of MCPyV status).
1MCPyV status was determined by PCR of tumor genomic DNA and complementary DNA (cDNA), as described in the text.
2Patient with history of chronic lymphocytic leukemia.
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P¼0.10). CD4þ T cells were scant in both MCPyV-positive
and MCPyV-negative tumors. CD20þ B cells were variable,
with no significant difference between groups (data not
shown).
In our cohort, most lymphocytes were in the peritumoral
stroma or associated with tumoral vessels, with only a
small number of tumor-infiltrating lymphocytes (TILs). We
observed a trend toward slightly increased CD8þ TILs in
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Figure 1. Principal component analysis of Merkel cell carcinoma (MCC)
transcriptional profiles relative to MCC cell lines and nonmelanoma skin
cancers. MCCs have a distinct expression profile compared with squamous cell
carcinomas (SCCs) and basal cell carcinomas (BCCs). Solid squares indicate
primary cutaneous SCCs. Solid circles indicate BCCs. Solid triangles indicate
MCC primary tumors. Open triangles indicate metastatic MCC tumors (Met).
Asterisks indicate MCC cell lines. PC1, principal component 1; PC2, principal
component 2.
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Figure 2. Principal component analysis of Merkel cell carcinoma (MCC)
tumors by Merkel cell polyomavirus (MCPyV) status. The majority of MCPyV-
positive tumors (open circles) display a distinct cluster that partially overlaps
with MCPyV-negative tumors (solid squares). MCPyV-negative tumors are
more heterogeneous. Negative: MCPyV T antigen (TAg) DNA and RNA
negative. Positive: TAg DNA and RNA positive. PC1, principal component 1;
PC2, principal component 2.
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Figure 3. Genes with greatest differential expression in Merkel cell polyomavirus (MCPyV)-positive tumors relative to MCPyV-negative tumors. All genes shown
have adjusted P-value p0.05. Fold values are in log2.
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Table 2. Functional gene classes enriched in MCPyV-negative compared with MCPyV-positive tumors
KEGG pathway1, probe set Gene Description Fold2
Axon guidance
229288_at EPHA7 EPH receptor A7 4.41
214607_at PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 4.72
231325_at UNC5D unc-5 homolog D (C. elegans) 4.29
200965_s_at ABLIM1 Actin binding LIM protein 1 3.53
227449_at EPHA4 EPH receptor A4 3.27
230425_at EPHB1 EPH receptor B1 4.06
209589_s_at EPHB2 EPH receptor B2 2.50
236088_at NTNG1 Netrin G1 2.36
213169_at SEMA5A Semaphorin 5A 2.03
223610_at SEMA5B Semaphorin 5B 2.16
32541_at PPP3CC Protein phosphatase 3, catalytic subunit, g isozyme 0.49
212298_at NRP1 Neuropilin 1 0.48
240425_x_at ROBO2 Roundabout, axon guidance receptor, homolog 2 (Drosophila) 0.43
227955_s_at EFNA5 Ephrin-A5 0.29
213603_s_at RAC2 rho family, small GTP binding protein Rac2 0.36
206941_x_at SEMA3E Semaphorin 3E 0.11
Pathways in cancer
208606_s_at WNT4 Wingless-type MMTV integration site family, member 4 3.94
203638_s_at FGFR2 Fibroblast growth factor receptor 2 2.75
210512_s_at VEGFA Vascular endothelial growth factor A 2.73
205463_s_at PDGFA Platelet-derived growth factor a polypeptide 2.25
230288_at FGF14 Fibroblast growth factor 14 2.06
227271_at FGF11 Fibroblast growth factor 11 2.07
227314_at ITGA2 Integrin, a2 (CD49B, a2 subunit of VLA-2 receptor) 2.25
221029_s_at WNT5B Wingless-type MMTV integration site family, member 5B 2.04
239178_a FGF9 Fibroblast growth factor 9 (glia-activating factor) 0.43
203132_at RB1 Retinoblastoma 1 0.41
223709_s_at WNT10A Wingless-type MMTV integration site family, member 10A 0.28
Notch signaling pathway
224215_s_at DLL1 Delta-like 1 (Drosophila) 4.99
201218_at CTBP2 C-terminal binding protein 2 2.71
203394_s_at HES1 Hairy and enhancer of split 1, (Drosophila) 2.50
32137_at JAG2 Jagged 2 2.35
216268_s_at JAG1 Jagged 1 2.25
Neuroactive ligand–receptor interaction
209990_s_at GABBR2 g-Aminobutyric acid (GABA) B receptor, 2 7.94
231192_at LPAR3 Lysophosphatidic acid receptor 3 5.98
221107_at CHRNA9 Cholinergic receptor, nicotinic, a9 4.41
231384_at GRIN2A Glutamate receptor, ionotropic, N-methyl D-aspartate 2A 2.69
209793_at GRIA1 Glutamate receptor, ionotropic, AMPA 1 2.62
213506_at F2RL1 Coagulation factor II (thrombin) receptor-like 1 2.30
229944_at OPRK1 Opioid receptor, k1 2.14
229309_at ADRB1 Adrenergic, b1-, receptor 2.0
230593_at GRIK3 Glutamate receptor, ionotropic, kainate 3 2.03
Table 2 Continued on following page
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MCPyV-positive tumors, which did not reach statistical
significance (fold 2.4, P¼0.06).
RB expression is decreased in MCPyV-negative MCCs
Previous reports have described increased RB protein expres-
sion in MCPyV-positive tumors (Bhatia et al., 2010b; Sihto
et al., 2011), although other reports found no association
(Houben et al., 2010; Schrama et al., 2011). We observed a
2.4-fold upregulation of RB1 in MCPyV-positive tumors by
microarray analysis (Table 2). By immunohistochemistry
analysis, 7/7 (100%) MCPyV-positive tumors were diffusely
positive (450% of cells) for the expression of RB protein
(Figure 4). In contrast, only 1/14 (7%) MCPyV-negative tumors
showed diffuse RB expression, 5 (36%) cases displayed
intermediate levels of expression (10–50% of cells), and 8
(57%) lacked significant expression.
DISCUSSION
Transcriptome profiling by DNA microarray analysis is a
powerful tool for identifying gene expression changes within
tumors and tumor subgroups. Here, we report gene expression
profiles of 30 MCCs, with direct comparison to 4 primary
cutaneous SCCs and 2 BCCs, as well as in silico comparison to
64 normal skin samples. In support of the biological validity of
our expression profiles, our screen identified upregulation of
diagnostic markers for MCCs, including CK20 and neuroendo-
crine markers, with respect to normal skin and SCCs. We also
identified increased expression of genes that may have
protumorigenic roles in MCCs, including FYN and FEV.
Further expression and functional studies are needed to
characterize the roles of these genes in MCCs.
Uncertainty regarding the cell of origin for MCCs contri-
butes to the difficulty in understanding the mechanisms of
MCC tumorigenesis. Historically, MCC was thought to arise
from Merkel cells, which are mechanoreceptor cells in the
basal epidermis that share immunohistochemical and ultra-
structural features with MCCs. However, this theory has been
debated because MCC often spares the epidermis, whereas
benign Merkel cells are intraepidermal (Plaza and Suster,
2006; Van Keymeulen et al., 2009). MCCs in our cohort
displayed differential regulation of genes with proposed roles
in mechanosensation and/or known expression in benign
Merkel cells (Haeberle et al., 2004; Chalfie, 2009; Coste
et al., 2010; Garrison et al., 2011). In addition, functional
gene set analysis identified that MCC was enriched for gene
clusters expressed in the inner ear, an organ with known
developmental similarities to benign Merkel cells. These
findings further demonstrate the similarity between MCCs
and benign Merkel cells.
The discovery and characterization of MCPyV has provided
a mechanism by which benign Merkel cells or progenitor stem
cells may undergo malignant transformation (Becker, 2010).
The mechanisms of tumorigenesis in MCPyV-negative MCCs
are less clear. Evidence suggests that tumors with low/absent
viral DNA and/or lack of LTAg expression are associated with
loss of RB expression (Bhatia et al., 2010a, b; Sihto et al.,
2011), increased c-KIT expression (Waltari et al., 2011),
increased p53 expression (Bhatia et al., 2010b; Waltari
et al., 2011), and TP53 mutations in a subset (Sihto et al.,
2011). Although previous studies have performed gene
expression microarray analysis of benign mouse Merkel
cells, MCC cell lines, and MCC tumors (Haeberle et al.,
2004; Paulson et al., 2011; Van Gele et al., 2004), these
studies did not compare gene expression profiles of MCPyV-
positive and MCPyV-negative tumors.
In MCPyV-positive MCCs, viral LTAg has been shown to
promote tumor growth by binding and inactivating the tumor-
suppressor protein RB (Shuda et al., 2008; Houben et al.,
2012). The role of RB in MCPyV-negative MCC pathogenesis
has been unclear, with some studies demonstrating decreased
RB expression (Bhatia et al., 2010a; Sihto et al., 2011),
whereas others finding no difference (Houben et al., 2010).
Our study demonstrated a 2.4-fold lower RB1 expression in
MCPyV-negative tumors relative to MCPyV-positive tumors by
gene expression microarray. Perhaps more significantly, the
majority of MCPyV-negative MCCs displayed the absence of
RB protein expression, whereas RB was diffusely expressed in
all MCPyV-positive tumors. Thus, loss of RB activity may be
integral to MCC pathogenesis, either through its inactivation
by LTAg in MCPyV-positive tumors or by loss of RB expression
Table 2. (Continued )
KEGG pathway1, probe set Gene Description Fold2
206128_at ADRA2C Adrenergic, a-2C-, receptor 0.41
205279_s_at GLRB Glycine receptor, b 0.38
211772_x_at CHRNA3 Cholinergic receptor, nicotinic, a3 0.36
229686_at P2RY8 Purinergic receptor P2Y, G-protein coupled, 8 0.39
213845_at GRIK2 Glutamate receptor, ionotropic, kainate 2 0.38
207307_at HTR2C 5-Hydroxytryptamine (serotonin) receptor 2C 0.38
Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; MCPyV, Merkel cell polyomavirus.
1KEGG pathways for each gene group are shown in bold. Note that although a functional class/pathway may be upregulated as a whole by KEGG analysis,
some individual genes within a class may not display upregulation.
2Fold change represents relative array transcript expression in MCPyV-negative Merkel cell carcinoma (MCC) relative to MCPyV-positive MCC. A central value
for each probe set was determined by averaging log-transformed data and taking the anti-logarithm.
PW Harms et al.
Expression Profiling of Merkel Cell Carcinoma
www.jidonline.org 941
in MCPyV-negative tumors. Deletions at the RB locus have
been described in MCCs (Leonard and Hayard, 1997; Van
Gele et al., 1998; Larramendy et al., 2004; Paulson et al.,
2009). A subset of MCPyV-negative tumors retained RB
expression, suggesting that an alternative mechanism of RB
pathway dysregulation may occur in these tumors.
The relationship of MCPyV status with various clinical
parameters is under active investigation. Age and stage at
presentation were not significantly related to MCPyV status in
our study. In agreement with previous reports (Paik et al.,
2011; Sihto et al., 2011), we observed a significantly higher
incidence of MCPyV-negative MCC tumors on the head and
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Figure 4. Merkel cell polyomavirus (MCPyV) negativity is associated with relatively decreased immune response and loss of RB expression. Relative to (a–c)
MCPyV-negative tumors, (d–f) MCPyV-positive tumors display a trend toward (a, d, g) increased CD3þ peritumoral lymphocytes, (b, e, g) low CD4þ T
lymphocytes, and (c, f, g) significantly increased CD8þ T lymphocytes by immunohistochemistry. (h, j) MCPyV-positive tumors uniformly express RB, (i, j)
whereas the majority of MCPyV-negative tumors display loss of RB expression by immunohistochemistry. Bar¼ 50mm.
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neck, whereas more MCPyV-positive MCC tumors were
located on the limbs. The incidence of MCPyV by PCR in
our cohort was lower (46%) than the commonly reported
70–80% (Bhatia et al., 2011). Because the influence of factors
such as immune status and geography on MCPyV incidence in
MCC is incompletely understood, we cannot rule out the
possibility that clinical/epidemiologic factors are affecting the
rate of MCPyV positivity in our cohort.
Several lines of evidence suggest that both cellular and
humoral responses occur in response to viral antigens
expressed in MCPyV-positive MCCs. Serum antibodies against
MCPyV TAg are relatively specific for the presence of active
MCCs, whereas antibodies against viral capsid proteins are
less specific (Carter et al., 2009; Pastrana et al., 2009; Paulson
et al., 2009; Tolstov et al., 2009; Faust et al., 2011). MCPyV-
reactive CD4þ and CD8þ T cells have been isolated from
MCPyV-positive MCC tumors, but are absent in MCPyV-
negative tumors (Iyer et al., 2011). Furthermore, one study
found that MCPyV-positive tumors are associated with
significantly increased CD3þ and CD8þ TILs, as well
as tumor-infiltrating monocytes, although another study did
not corroborate these findings with respect to CD8þ T cells
(Paulson et al., 2011; Sihto et al., 2012). By GO analysis,
we observed increased expression of immune response genes
in MCPyV-positive tumors, consistent with the presence of
increased tumoral lymphocytes. Immunohistochemistry
revealed significantly increased CD8þ T cells in the
peritumoral stroma of MCPyV-positive tumors. Together
with previous studies, our results indicate that MCPyV-
associated cellular immune response appears to consist
predominantly of CD8þ lymphocytes (Iyer et al., 2011;
Sihto et al., 2012), although we observed the immune
response to consist of predominantly peritumoral
lymphocytes rather than TILs.
In summary, we report a transcriptome-wide comparison of
MCPyV-positive MCCs with MCPyV-negative MCCs. RB
expression is lost in the majority of MCPyV-negative tumors,
supporting the concept that RB deregulation is a key alteration
in MCCs. Our data are in keeping with the notion of two
distinct classes of MCCs based on viral status. Further studies
evaluating the Notch pathway and receptor tyrosine kinases
are underway to elucidate their role in the pathogenesis of
MCCs.
MATERIALS AND METHODS
Tumor procurement and cell lines
Studies were approved by the Institutional Review Board of the
University of Michigan. For all tumors, MCC diagnosis was confirmed
by morphology and immunohistochemistry at the time of diagnosis.
All tumor tissues were procured from the University of Michigan
Hospitals Cutaneous Surgery and Oncology Program. At the time of
collection, tumor tissue was flash-frozen in liquid nitrogen and stored
at  80 1C until RNA extraction. Formalin-fixed, paraffin-embedded
tissue for tissue microarray construction was obtained from archival
tissue blocks. The adequacy of frozen section and paraffin-embedded
tissue was confirmed by two pathologists (DRF and PWH).
RNA was prepared from normal skin and processed for microarray
analysis as previously described (Gudjonsson et al., 2009).
The MCC cell lines were established at the University of Michigan
from tumor tissue procured as described above, with additional
details on cell line establishment in Supplementary Materials and
Methods online.
RNA isolation
Areas with at least 70% tumor cellularity were targeted for RNA
isolation, using hematoxylin and eosin stains obtained on frozen
sections for each specimen. Representative 2-mm3 areas were
removed from the tissue block and homogenized in the presence of
Trizol reagent (Life Technologies, Gaithersburg, MD), and total
cellular RNA was purified according to the manufacturer’s standard
protocol. RNA was then further purified using miRVANA (Ambion,
Austin, TX) according to the manufacturer’s protocol. After
purification, RNA quality was assessed by Agilent Bioanalyzer
(Agilent, Santa Clara, CA).
cRNA synthesis and gene expression profiling
Human 133 Plus 2.0 microarrays (Affymetrix, Santa Clara, CA) were
used, which consist of 454,000 probe sets representing B47,400
transcripts. Preparation of cRNA hybridization was performed accord-
ing to the manufacturer’s protocols. GeneChips were scanned using
the Affymetrix 3000 7G GeneChip Scanner with Autoloader and
processed by the Affymetrix Gene Chip Command Console version
3.2. Samples were analyzed in two batches, with overlapping speci-
mens included to control for batch effect. Because of the lack of
overlapping samples, batch effect could not be corrected for the
in silico comparison between MCCs and normal skin. Expression data
have been made available in the Gene Expression Omnibus (GEO)
database (accession number GSE39612).
Statistical analysis
For DNA microarrays, log2 gene expression values were calculated
using a robust multiarray average. Adjusted P-value was calculated
using the Benjamini and Hochberg False Discovery Rate concept
(Benjamini and Hochberg, 1995). For all analyses, a fold change of
X2.0 or p0.5 with an adjusted P-value of p0.05 was considered
statistically significant. Array quality was evaluated by standard error
estimates for each gene standardized across all arrays after fitting a
probe level model using the affyPLM package of Bioconductor
(Bolstad et al., 2005). One sample was eliminated owing to elevated
standard errors. Age was described and tested between MCPyV-
positive and MCPyV-negative groups using means, SD, and corres-
ponding t-tests. Anatomical site was compared between MCPyV
groups with Fisher’s exact test. Further details on statistical analyses
are provided in Supplementary Materials and Methods online.
Characterization of MCPyV status in MCC tumors
PCR of isolated genomic tumor DNA was performed to detect the
presence of MCPyV DNA in tumor samples. Because tumors that
contain MCPyV DNA but lack LTAg expression are reported to be
more similar to MCPyV-negative tumors with regard to clinical
outcome (Sihto et al., 2011), we also characterized RNA expression
of MCPyV LTAg and STAg by reverse transcription PCR. Tumor
RNA was used to prepare complementary DNA according to
standard protocols. Briefly, 0.25mg of RNA was used for first-strand
complementary DNA synthesis with SuperScript II Reverse
Transcriptase (Invitrogen, Carlsbad, CA) as per the manufacturer’s
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instructions. Detection of MCPyV sequence (based on GenBank
NC_010277) was conducted by semiquantitative PCR on tumor
complementary DNA and/or genomic DNA using primers TA1,
targeting the exon 1 coding region common to all T antigen
transcripts (forward primer: nucleotides (nts) 226–245, reverse primer:
nts 357–376), and TA2, targeting the exon 1 coding region specific to
STAg only (forward primer: nts 354–373, reverse primer: nts 571–
590). Results were further confirmed using the previously described
primers for capsid viral protein (VP1) (Feng et al., 2008). Human b-
actin primers were used as a control. As a control for a gene
expressed in MCC, primers were used for atonal homolog 1
(GenBank NP_005163; forward primer: nts 230–249, reverse primer:
nts 444–463). All primers were designed using Primer3 (http://
fokker.wi.mit.edu/primer3/input.htm). PCR products were separated
by agarose gel and visualized by ethidium bromide. Three tumors
were excluded owing to insufficient tissue or degraded DNA. An
additional tumor was excluded because of equivocal results for TAg
mRNA expression. Of the remaining 26 tumors, 12 (46%) had both
MCPyV DNA and mRNA, and 14 (54%) lacked both MCPyV DNA
and mRNA.
Immunohistochemistry
A tissue microarray of profiled tumors was constructed, with each
tumor represented by two 1.0-mm cores. Tumor content of each core
was verified by hematoxylin and eosin staining. Immunohistochem-
istry was performed using a DAKO automated stainer (DAKO,
Carpinteria, CA) as previously described (Yu et al., 2010).
Antibodies and dilutions are described in Supplementary Materials
and Methods online.
For RB, the percentage of tumor cells labeled was recorded as one
of three categories: o10% (negative), 10–50% (intermediate), and
450% (diffuse). All positive cases displayed a nuclear pattern of
staining. RB staining was compared between MCPyV groups with
Fisher’s exact test.
For CD20, CD3, CD4, and CD8, peritumoral lymphocytes and TILs
were counted across two 1-mm tissue microarray cores for each
tumor. Wilcoxon rank test was used to test differences in CD20þ ,
CD3þ , CD4þ , and CD8þ peritumoral lymphocyte and TIL
measures between MCPyV groups.
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